This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

10 Biotech Stocks Expected to at Least Double

4. Avanir Pharmaceuticals (AVNR) acquires, develops and commercializes drugs for central nervous system disorders. Lead product candidate Zenvia for pseudobulbar affect has completed three Phase III clinical trials. Avanir's second-quarter loss widened 15% to $5.7 million, but remained steady on a per share basis, at 6 cents. Revenue declined 18%. Avanir's stock sells for a book value multiple of 9.7 and a sales multiple of 76, massive premiums to pharmaceutical peer averages. Of analysts following Avanir, all four advise purchasing its shares.

Bullish Scenario: Jefferies (JEF) offers a target of $10, implying the stock will more than triple.

7 of 10

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Submit an article to us!
SYM TRADE IT LAST %CHG
AAPL $125.80 0.00%
FB $77.56 0.00%
GOOG $530.80 0.00%
TSLA $232.95 0.00%
YHOO $41.30 0.00%

Markets

DOW 17,928.20 -142.20 -0.79%
S&P 500 2,089.46 -25.03 -1.18%
NASDAQ 4,939.3270 -77.6020 -1.55%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs